Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial
FLYER Trial Investigators, German Lymphoma Alliance
Research output: Contribution to journal › Article › peer-review
155Scopus
citations
Fingerprint
Dive into the research topics of 'Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial'. Together they form a unique fingerprint.